Methods |
Trial design: randomised, multicentre, double‐blind study Sample size: 260 Setting: inpatient Language: Italian, English Number of centres: 5 Type of intervention (treatment/prevention): treatment |
Participants |
Inclusion criteria
Age = 18 years
Informed consent for participation in the study and for data processing
Molecular diagnosis with PCR test of Sars‐CoV2 infection
Hospitalisation in a specialist ward for COVID‐19 patient care (e.g. Infectious Diseases, Pulmonology or Internal Medicine)
Need for supplemental oxygen in any delivery mode with the exception of IMV
PaO2/FiO2 between 100 and 300 mmHg
Clinical/instrumental diagnosis (high‐resolution chest CT scan or chest X‐ray or lung ultrasound) of interstitial pneumonia for no more than 3 days
Serum CRP > 5 mg/dL
Interval from onset of SARS‐CoV2 infection symptoms to randomisation > 5 days
Exclusion criteria
IMV
Presence of shock or concomitant organ failure that requires admission to the ICU
Pregnancy or breastfeeding
Severe heart or kidney failure
Known hypersensitivity to methylprednisolone, to dexamethasone or to an exception
Diabetes not compensated according to the doctor's judgement
Other clinical conditions that contraindicate methylprednisolone and cannot be treated or resolved according to the doctor's judgement
Steroid bolus therapy in the week prior to enrolment for the study
Enrolment in another clinical trial
Patient already randomised in this study
|
Interventions |
Details of intervention:
Treatment details of control group (e.g. dose, route of administration): placebo, IV Concomitant therapy: no information |
Outcomes |
Primary study outcome: length of hospitalisation, calculated as the interval between randomisation and discharge from the hospital without the need for supplemental oxygen |
Notes |
Recruitment status: completed Prospective completion date: 4‐month trial duration planned Date last update was posted: 25 November 2020 Sponsor/funding: Azienda Ospedaliera Arcispedale Santa Maria Nuova/IRCCS Di Reggio Emilia |